Techno Drugs (DHA:TECHNODRUG) Research & Development: BDT0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:TECHNODRUG Techno Drugs Ltd DHA:TECHNODRUG
37 GF Score
Price BDT47.30
! 10 Warning Signs
View Full Analysis

What is Techno Drugs Research & Development?

Techno Drugs DHA:TECHNODRUG -2.27% 37 Research & Development is BDT0 Mil as of Mar. 2026. GuruFocus rates DHA:TECHNODRUG with a GF Score™ of 37/100. The stock has 10 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Techno Drugs's Research & Development for the three months ended in Mar. 2026 was BDT0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was BDT0 Mil.

Techno Drugs  (DHA:TECHNODRUG) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Techno Drugs Research & Development Related Terms

Techno Drugs Research & Development Historical Data

* Premium members only.

The historical data trend for Techno Drugs's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Techno Drugs Research & Development Chart

Techno Drugs Annual Data
Trend Jun24 Jun25
Research & Development
0.00 0.00

Techno Drugs Quarterly Data
Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
DHA:TECHNODRUG
37GF Score
Techno Drugs Ltd DHA:TECHNODRUG
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Techno Drugs Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of BDT0 Mil mean?
Techno Drugs (DHA:TECHNODRUG) has a Research & Development of BDT0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Techno Drugs and its competitors.
Is Techno Drugs' Research & Development too high?
Techno Drugs' current Research & Development is BDT0 Mil. Overall, Techno Drugs has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Techno Drugs' Research & Development compare to ZTS and UTHR?
Techno Drugs' Research & Development of BDT0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Techno Drugs and its competitors. Techno Drugs's current Research & Development is BDT0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Techno Drugs stock overvalued right now?
Techno Drugs (DHA:TECHNODRUG) has a current Research & Development of BDT0 Mil. The current Research & Development is BDT0 Mil. Techno Drugs' overall GF Score™ is 37/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Techno Drugs (DHA:TECHNODRUG), the current Research & Development is BDT0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Techno Drugs Business Description

Address 31 Segun Bagicha, J K Tower, Dhaka, BGD, 1000
Techno Drugs Ltd is a pharmaceutical company. The company manufactures medicines for the healthcare market with quality products, a distribution channel, and doctor-patient acceptance. The company is also engaged in production of Anti-Cancer medicines and medicines for therapeutic areas like oncology, cardiovascular, diabetes, immune suppressor, anesthetics, life-saving antibiotics & contrast media in Bangladesh. The product portfolio of the company include Algicar Plus, Amoclav Forte, Adesol Oral Solution, Aminovet Injection, Apegestrol Tab, Docetex 20 Inj, and others.
37GF Score

Get the complete analysis for DHA:TECHNODRUG

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT47.30
Price